{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:55:31Z","timestamp":1768006531044,"version":"3.49.0"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1509,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1111\/j.1600-0609.2011.01634.x","type":"journal-article","created":{"date-parts":[[2011,4,27]],"date-time":"2011-04-27T15:39:28Z","timestamp":1303918768000},"page":"117-122","source":"Crossref","is-referenced-by-count":17,"title":["Melphalan 100\u2003mg\/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation"],"prefix":"10.1111","volume":"87","author":[{"given":"Cecilie","family":"Blimark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ljupco","family":"Veskovski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Westin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stig","family":"R\u00f6djer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats","family":"Brune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Hjorth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per-Ola","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf-Henrik","family":"Mellqvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,7,15]]},"reference":[{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB2|cit2","first-page":"7","article-title":"Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60\u2003years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group","volume":"95","author":"Lenhoff","year":"2000","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1182\/blood-2009-08-238196","article-title":"Hematopoietic stem cell transplantation for multiple myeloma beyond 2010","volume":"115","author":"Blade","year":"2010","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1600-0609.2005.00533.x","article-title":"Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant","volume":"75","author":"Palumbo","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2047-783X-15-1-13","article-title":"Bendamustine in patients with relapsed or refractory multiple myeloma","volume":"15","author":"Michael","year":"2010","journal-title":"Eur J Med Res"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2003.01.055","article-title":"DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma","volume":"21","author":"Lee","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood.V76.4.677.677","article-title":"High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma","volume":"76","author":"Barlogie","year":"1990","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1365-2141.1996.00306.x","article-title":"Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma","volume":"92","author":"Lokhorst","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood.V94.4.1248","article-title":"Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients","volume":"94","author":"Palumbo","year":"1999","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00277-009-0862-z","article-title":"Salvage treatment with upfront melphalan 100\u2003mg\/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma","volume":"89","author":"Krejci","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/bmt.2008.334","article-title":"Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma","volume":"43","author":"Olin","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3816\/CLM.2006.n.028","article-title":"Intermediate-dose melphalan (100\u2003mg\/m2)\/bortezomib\/thalidomide\/dexamethasone and stem cell support in patients with refractory or relapsed myeloma","volume":"6","author":"Palumbo","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB16|cit16","first-page":"141","article-title":"The role of second autografts in the management of myeloma at first relapse","volume":"91","author":"Alvares","year":"2006","journal-title":"Haematologica"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.bmt.1703715","article-title":"Transplantation as salvage therapy for high-risk patients with myeloma in relapse","volume":"30","author":"Lee","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/cncr.21700","article-title":"Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma","volume":"106","author":"Qazilbash","year":"2006","journal-title":"Cancer"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/asheducation-2010.1.303","article-title":"Relapsed Multiple Myeloma","volume":"2010","author":"Lonial","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1634\/theoncologist.2009-0203","article-title":"Current multiple myeloma treatment strategies with novel agents: a European perspective","volume":"15","author":"Ludwig","year":"2010","journal-title":"Oncologist"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ajh.21913","article-title":"Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"Rajkumar","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1600-0609.2009.01257.x","article-title":"Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma","volume":"82","author":"Stadtmauer","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB25|cit25","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.946.946","article-title":"Second autologous stem cell transplant (ASCT) as salvage therapy in patients with relapsed multiple myeloma: Improved outcomes in patients with longer disease free interval after first ASCT","volume":"110","author":"Mikhael","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/10245330500234369","article-title":"Re-use of the original infusional induction chemotherapy as salvage therapy in myeloma patients relapsing after one autograft","volume":"10","author":"Sirohi","year":"2005","journal-title":"Hematology"},{"key":"10.1111\/j.1600-0609.2011.01634.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.bbmt.2010.04.002","article-title":"Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma","volume":"16","author":"Novitzky","year":"2010","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2011.01634.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0609.2011.01634.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T05:37:09Z","timestamp":1625636229000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2011.01634.x"}},"subtitle":["Mel 100 for myeloma patients in first relapse"],"short-title":[],"issued":{"date-parts":[[2011,7,15]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01634.x","relation":{},"ISSN":["0902-4441"],"issn-type":[{"value":"0902-4441","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7,15]]}}}